The 12 closest competitors and alternatives to Otsuka Pharmaceutical Co., Ltd. among pharmaceuticals companies — ranked by similarity to what Otsuka Pharmaceutical Co., Ltd. actually does, not by market-cap band.
Subscribe to see Otsuka Pharmaceutical Co., Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Chiyoda, Tokyo, Japan. The company's philosophy is "Otsuka-people creating new products for better health worldwide."
Otsuka Pharmaceutical Co., Ltd. is a pharmaceuticals company headquartered in Japan. Xcout tracks 1 named person at Otsuka Pharmaceutical Co., Ltd., including 井上 眞 (代表取締役社長).
Ranked by semantic similarity — how close each company is to Otsuka Pharmaceutical Co., Ltd. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
Similar pharmaceuticals company
Otsuka America Pharmaceutical, Inc. is a healthcare and pharmaceutical company headquartered in Princeton, New Jersey, operating within the United States.
Similar pharmaceuticals company
Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company, and a subsidiary of Otsuka Holdings, which focuses on developing cancer treatments. Taiho, headquartered in Tokyo, Japan, is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.
Similar pharmaceuticals company
Astellas Pharma Inc. is a Japanese pharmaceutical company headquartered in Tokyo. The company has global offices and research centers.
Similar pharmaceuticals company
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
Similar pharmaceuticals company
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.
Similar pharmaceuticals company
Santen Pharmaceutical Co., Ltd. is headquartered in Osaka, Japan, and is a global leader in ophthalmological research, development, production, and marketing of related pharmaceuticals and medical devices.
Similar pharmaceuticals company
Avanir Pharmaceuticals is a specialty pharmaceutical company known for developing and commercializing treatments for neurological disorders, particularly NUEDEXTA (dextromethorphan/quinidine) for pseudobulbar affect. It serves patients with neurological conditions and the healthcare professionals who treat them; Avanir became part of Otsuka America, Inc. in 2015.
Similar pharmaceuticals company
Sanofi K.K. is a subsidiary company located in Tokyo-to, Japan. It is involved in the manufacture of pharmaceutical products.
Similar pharmaceuticals company
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Similar pharmaceuticals company
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Similar pharmaceuticals company
Chong Kun Dang Pharmaceutical Corp. is a leading Korean pharmaceutical company. The company's ideology is to implement a healthy society without diseases, and it has expanded its operations with an office in Vietnam and a joint venture in Indonesia.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Otsuka Pharmaceutical Co., Ltd.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →